Ingram Micro added to S&P SmallCap 600, replacing Pacira BioSciences
Ingram Micro Holding Corp. will replace Pacira BioSciences in the S&P SmallCap 600 on November 17, 2026, after Pacira’s pending acquisition by Viatris. The index change was announced by S&P Dow Jones Indices and follows Viatris’ $1.65 billion cash deal for Pacira. Ingram Micro reported third‑quarter net sales of $15.2 billion, up 20.8% YoY, and GAAP net income of $131.1 million, up 31.8% YoY.
Why it matters
The addition may draw passive fund inflows into Ingram Micro as the index is widely tracked (the company noted the move could attract such inflows). Pacira’s removal ends its exposure to SmallCap 600 investors, while Viatris’ acquisition creates the vacancy that prompted the substitution.
Key facts
- 1Effective date of the index change is November 17, 2026. prnewswire.com
- 2Ingram Micro will replace Pacira BioSciences in the S&P SmallCap 600. prnewswire.com
- 3Viatris is acquiring Pacira BioSciences for an aggregate equity value of US$1.65 billion. securities.io
- 4The acquisition price is $36.50 per Pacira share in cash. securities.io
- 5Ingram Micro reported Q3 net sales of $15.2 billion, up 20.8% year over year. securities.io
- 6Ingram Micro reported GAAP net income of $131.1 million for Q3, up 31.8% year over year. securities.io
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.